Journal
LANCET RESPIRATORY MEDICINE
Volume 1, Issue 7, Pages 551-563Publisher
ELSEVIER SCI LTD
DOI: 10.1016/S2213-2600(13)70159-0
Keywords
-
Categories
Funding
- Universite Paris Descartes
- Ligue contre le Cancer
- Agence Nationale de la Recherche (ANR)
- Association pour la Recherche contre le Cancer (ARC)
- Canceropole and Region Ile de France
- Institut National du Cancer (INCA)
- Labex Immuno-Oncology, Site de Recherche Integree sur le Cancer Stratified Oncology Cell DNA Repair And Tumor immune Elimination (SIRIC SOCRATES)
- Paris Alliance of Cancer Research Institutes (PACRI)
- CAncer Research and PErsonalized Medicine (CARPEM)
Ask authors/readers for more resources
Lung cancer is the most common cause of cancer-related mortality worldwide and a therapeutic challenge. Recent success with antibodies blocking immune checkpoints in non-small-cell lung cancers (NSCLC) highlights the potential of immunotherapy for lung cancer treatment, and the need for trials of combination regimens of immunotherapy plus chemotherapy that lead to immunogenic cell death. Here, we review the development of immunogenic cytotoxic compounds, vaccines, and antibodies in NSCLC, in view of their integration into personalised oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available